Strategy, Yield and Risks of Controlling Plasma Lipids in the Primary Prevention of Coronary Heart Disease

  • M. F. Oliver


Reduction of plasma cholesterol and cholesterol-containing lipoproteins, or an increase in high density lipoproteins, is widely accepted as the desired goal for the whole population. It is time that a more critical appraisal is made of this aim in terms of the likely yield and practicability of such a policy.


Coronary Heart Disease Serum Cholesterol Mass Intervention Blood Lipid Level Lipid Research Clinic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    I. Holme, S. C. Enger, A. Helgeland, I. Hjermann, Paul Leren, P. G. Lund-Larson, L. A. Solberg, and J. P. Strong, Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries, Statistical analysis from the Oslo Study, Arteriosclerosis 1: 250 – 256 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    The Pooling Project Research Group, Relationship of blood pressure serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events, Final report of the Pooling Project, J. Chron. Dis. 31: 201 – 306 (1978).CrossRefGoogle Scholar
  3. 3.
    G. Rose, P. J. S. Hamilton, H. Keen, D. D. Reed, P. McCartney, and R. J. Jarrett, Myocardial ischaemia, risk factors and death from coronary heart disease, Lancet 1: 105 – 109 (1977).PubMedCrossRefGoogle Scholar
  4. 4.
    U. Goldbourt and J. H. Medalie, Lipoprotein cholesterol and the incidence of coronary heart disease - the Israeli Ischaemic Heart Disease Study, AMA. J. Epidemiol. 109: 296 – 307 (1975).Google Scholar
  5. 5.
    L. E. Bottiger and L. A. Carlson, Risk factors for ischaemic vascular death from men in the Stockholm Prospective Study, Atherosclerosis 36: 389 – 408 (1980).CrossRefGoogle Scholar
  6. 6.
    W. P. Castelli, R. D. Abbott, and P. M. McNamara, Summary estimates of cholesterol used to predict coronary heart disease, Circulation 67: 730 – 734 (1983).PubMedCrossRefGoogle Scholar
  7. 7.
    F. H. Epstein, in: “Prevention and Treatment of Coronary Heart Disease and its Complications”, Excerpta Medica, Amsterdam, pp. 1–11 (1980).Google Scholar
  8. 8.
    M. F. Oliver, The optimum serum cholesterol, Lancet 2: 655 (1982).CrossRefGoogle Scholar
  9. 9.
    M. F. Oliver, Should we not forget about mass control of coronary risk factors? Lancet 2: 37 – 38 (1983).PubMedCrossRefGoogle Scholar
  10. 10.
    S. Dayton, M. L. Pearce, S. Hashimoto, W. J. Dixon, and U. Tomiyasu, A controlled clinical trial of a diet high in unsaturated fat in preventing complications in atherosclerosis, Circulation 39,40; Suppl. 2: 1 – 63 (1969).Google Scholar
  11. 11.
    O. Turpeinen, M. J. Karvonen, M. Pekkarinen, M. Miettinen, R. Elosuo, and E. Paavilainen, Dietary prevention of coronary heart disease, The Finnish Mental Hospital Study, Int. J. Epidemiol. 8: 99 – 118 (1979).PubMedCrossRefGoogle Scholar
  12. 12.
    Report from the Committee of Principal Investigators, A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate, Brit. Heart J. 10: 1069 – 1118 (1978).Google Scholar
  13. 13.
    P. Puska, J. Tuomilehto, J. Salonen, L. Neittaaumaki, J. Maki, J. Virtamo, A. Nissinen, K. Koskela, and T. Takalo, Changes in coronary risk factors during comprehensive five-year community programme to control cardiovascular diseases (North Karelia Project), Brit. Med. J. 4: 1173 – 1178 (1979).CrossRefGoogle Scholar
  14. 14.
    J. T. Salonen, P. Puska, and H. Mustaniemi, Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–77 in North Karelia, Brit. Med. J. 4: 1178 – 1183 (1979).CrossRefGoogle Scholar
  15. 15.
    J. T. Salonen, P. Puska, T. E. Kottke, J. Tuomilehto, A. Nissinen, Decline in mortality from coronary heart disease in Finland from 1969–1979, Brit. Med. J. 286: 1857 – 1860 (1983).CrossRefGoogle Scholar
  16. 16.
    Multiple Risk Factor Intervention Trial, JAMA 248: 1465 – 1468 (1982).CrossRefGoogle Scholar
  17. Report of a WHO Expert Committee, Prevention of coronary heart disease, World Health Organisation Technical Report Series 678 (1982)Google Scholar
  18. 18.
    A. Keys, J. T. Anderson, and F. Grande, Serum cholesterol response to changes in the diet. I. Iodine value of dietary fat versus 2S-P, Metabolism 14:747–758; 766 – 775 (1965).CrossRefGoogle Scholar
  19. 19.
    World Health Organisation, European Collaborative Group, Multifactorial Trial in the Prevention of Coronary Heart Disease. 3. Incidence and Mortality Results, Eur. Heart J. 4: 141 – 147 (1983).Google Scholar
  20. 20.
    M. Kornitzer, G. DeBacker, M. Dramaix, F. Kittel, C. Thilly, M. Graffar, and K. Vaylsteek, Belgian Heart Disease Prevention Project: Incidence of mortality results, Lancet 1: 1066 – 1070 (1983).PubMedCrossRefGoogle Scholar
  21. 21.
    G. Rose, H. D. Tunstall-Pedoe, and R. F. Heller, U. K. Heart Disease Prevention Project: Incidence and mortality results, Lancet 1: 1062 – 1065 (1983).PubMedCrossRefGoogle Scholar
  22. 22.
    M. Feinleib and B. M. Rifkind, Changing patterns of cardiovascular disease mortality in the United States, Israel J. Med. Sci. 18: 1098 – 1105 (1982).PubMedGoogle Scholar
  23. 23.
    L. Wellin, B. Larsson, K. Svardsudd, L. Wilhelmsen, and G. Tibblin, Why is the incidence of ischaemic heart disease in Sweden increasing? Study of men born in 1913 and 1923, Lancet 1: 1087 – 1089 (1983).CrossRefGoogle Scholar
  24. 24.
    L. Alfredsson and A. Ahlbom, Increasing incidence in mortality from myocardial infarction in Stockholm county, Brit. Med. J. 286: 1931 – 1933 (1983).Google Scholar
  25. 25.
    U. Goldburt and J. D. Kark, Changing patterns of cardiovascular disease mortality in the United States, Israel J. Med. Sci. 18: 1077 – 1097 (1982).Google Scholar
  26. 26.
    E. Guberan, Surprising decline of cardiovascular mortality in Switzerland, 1951–56, J. Epidemiol. Comm. Health 33: 114 – 120 (1979).CrossRefGoogle Scholar
  27. 27.
    I. Hjermann, I. Holme, K. V. Byre, and P. Leren, The effect of diet and smoking intervention on the incidence of coronary heart disease, Lancet 2: 301 – 310 (1981).Google Scholar
  28. 28.
    Report of the Committee of Principal Investigators, In preparation.Google Scholar
  29. 29.
    H. O. Perry, R. K. Winkelmann, R. W. P. Achor, and T. J. Kirby, Side effects of triparanol therapy, Am. J. Med. Sci. 244: 556 – 563 (1962).CrossRefGoogle Scholar
  30. 30.
    A. E. Dorr, K. Gunderson, J. C. Schneider, Jr., T. W. Spencer, and W. B. Martin, Colestipol hydrochloride in hypercholesterolaemic patients - effect on serum cholesterol and mortality, J. Chron. Dis. 31: 5 – 14 (1978).PubMedCrossRefGoogle Scholar
  31. 31.
    Lipid Research Clinics Program, The Coronary Primary Prevention Trial: Pesign and Implementation, J. Chron. Dis. 32: 609 – 631 (1979).CrossRefGoogle Scholar
  32. 32.
    M. F. Oliver, Risk of correcting the risk of coronary disease and stroke with drugs, New Engl. J. Med. 306: 297 – 298 (1982).PubMedCrossRefGoogle Scholar
  33. 33.
    Medical Research Council Working Party on Mild to Moderate Hypertension, Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension, Lancet 2: 539 – 543 (1981).Google Scholar
  34. 34.
    P. K. Whelton, P. Brennan, W. E. Miall, G. Greenberg, B. Subramanian, Thiazide associated cardiac arrhythmias, Circulation 66:Suppl. 2 – 238 (1982).Google Scholar
  35. 35.
    M. F. Oliver, Poctors and the drug industry, Brit. Med. J. 286: 888 – 889 (1983).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • M. F. Oliver
    • 1
  1. 1.Cardiovascular Research UnitUniversity of EdinburghEdinburghScotland

Personalised recommendations